An Early Phase 1 interventional study of Metformin in Obesity, Hyperandrogenemia and Polycystic Ovary Syndrome, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to female participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-10-27.
Sponsored by University of Virginia · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing metformin in Obesity — 15 open to participants now, 17 under way, 3 of them phase 3. Metformin · Obesity.
Among the 81 studies testing metformin in Obesity, this one is the 72nd largest by planned enrollment, is one of 5 that started in 2017, is one of 9 in phase 1, reaches primary completion later than 2 of the 16 other live ones, and was the 29th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →15 of the 81 studies testing metformin in Obesity are open now, in 9 countries. Recruiting first, the newest first:
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Riphah International University · Sites in Pakistan
Healthy volunteers
Fazaia Ruth Pfau Medical College · Sites in Pakistan
Ages 18–45
Fudan University · Sites in China
Ages 60–75
University Of Nigeria Teaching Hospital · Sites in Nigeria
Ages 20–59
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 7 Years to 18 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 13 · Phase 4 29
First in 1996; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 62 across the 81 interventional studies. Of the 55 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 81 have an industry lead sponsor. The 10 most frequent:
University of Virginia is the lead sponsor of 677 studies on the registry; 139 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.
23 studies in Obesity by University of Virginia: 7 open now, 10 under way, 1 of them phase 3. Of 5 finished, 1 (20%) have results posted.
Among the 23 studies in Obesity by University of Virginia, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2017, is one of 4 in phase 1, and was the 10th registered.
University of Virginia’s Obesity studies by the year they started, since 2001.
8 of the studies testing metformin in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07297290Phase 3University Of Nigeria Teaching HospitalEffect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI) | 2027-03-31 |
| NCT07622290Phase 3Prof Ibrahim JanahiMetformin Treatment for Children With Obesity-associated Asthma | 2027-08 |
| NCT07550816Beijing QL Biopharmaceutical Co.,LtdDrug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | 2026-12-05 |
| NCT06273072Johns Hopkins UniversityMetformin IN Asthma for Overweight and Obese Individuals (MINA) | 2026-12-31 |
| NCT05744479Centre for Addiction and Mental HealthMetformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability | 2027-03-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 81 studies testing metformin in Obesity, from their registry updates:
Among University of Virginia’s 23 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will test whether metformin administration can ameliorate androgen (male hormone) overproduction in overweight pubertal girls with androgen excess. The investigators hypothesize that improvement in insulin sensitivity by 12 weeks of metformin administration will improve androgen levels after adrenal stimulation testing with adrenocorticotropic hormone (ACTH) or ovarian stimulation testing with recombinant human chorionic gonadotropin (rhCG).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
Drug: Metformin
500-1000 mg PO BID (X12 weeks)
Also known as: Glucophage
Changes in free testosterone or 17-hydroxyprogesterone levels after ACTH and rhCG administration respectively, before and after metformin administration for 12 weeks
Time frame: 12 weeks after metformin administration
Changes in adrenal and ovarian steroid precursors after ACTH and rhCG; body composition via air displacement plethysmography, BMI, and glucose tolerance testing results; baseline and after 12 weeks of metformin administration
Time frame: 12 weeks after metformin administration
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2017 (actual). Primary completion is estimated for Dec 2024, 93 months after the start.
Of 105 non-industry phase 1 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 57. This study's planned 93 months is above that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin